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FORMULASI DAN PENILAIAN GEL ETOSOM BERMUATAN 
COLCHICIN UNTUK PENGHANTARAN TRANSDERMAL 
 
ABSTRAK 
                  Colchicin digunakan untuk rawatan gout, pseudo-gout dan demam 
Mediterranean. Ia diketahui mempunyai terapetik indeks rendah dan biokeperolehan 
oral rendah yang disebabkan oleh kesan laluan pertama yang teruk, dan ia juga 
dikaitkan dengan kesan sampingan gastrousus teruk berikutan pemberian oral. Untuk 
mengatasi kelemahan pengambilan oral, gel etosom bermuatan colchicin disediakan 
dalam usaha untuk penghantaran drug secara transdermal. Tiga jenis etosom pembawa 
nano telah disediakan dengan menggunakan kaedah sejuk. Lima set reka bentuk 
faktorial eksperimen telah dijalankan, satu factorial 23 untuk etosom klasik, satu 
factorial 24 untuk etosom binari, dan tiga factorial 24 untuk transetosom. Sistem etosom 
dengan purata saiz vesikel  ≤ 150 nm, polydispersity indeks (PdI) ≤ 0.3, dan zeta 
berpotensial (ZP) ≥ -20 mV dikaji lebih lanjut untuk penggabungan drug dalam 
etosom. Sistem etosom optimum dengan kecekapan pemerangkapan > 75 %, 
kemudian digabungkan ke dalam gel asas (Carbopol 940®). Gel etosom itu dicirikan 
mengikut purata saiz vesikel, PdI, ZP, pH, kelikatan dan nilai alah. Semua formulasi 
gel etosom menujukkan aliran plastik bukan Newtonian tanpa thixotropy. Dua gel 
etosom optimum dipilih iaitu TET 2 dan TENa 4 gel. Gel TET 2 memiliki purata saiz 
vesikel, PdI, ZP, pH, kelikatan dan nilai alah,  masing-masing 111.4 ± 1.6 nm, 0.157 
± 0.01, -40.56 ± 5.32 mV, 6.74 ± 0.05, 66.25 ± 2.75 Pa.s, 131.91 ± 1.94 Pa.  Manakala 
TENa 4 gel memiliki purata saiz vesikel, PdI, ZP, pH, kelikatan dan nilai alah masing-
masing 110.5 ± 1.1 nm, 0.162 ± 0.014, -43.54 ± 2.56 mV, 6.81 ± 0.04, 55.68 ± 0.76 
xx 
 
Pa.s, 122.71 ± 0.99 Pa. Kaedah HPLC dibangunkan dan divalidasi bagi kuantifikasi 
colchicin dalam gel etosom dan dalam cecair media.  Kajian ex-vivo ketelapan kulit 
dijalankan untuk menilai dan membandingkan parameter ketelapan kulit antara 
formulasi gel etosom optimum dan gel bukan etosom. Formulasi gel TET 2 
mempunyai penelapan kulit lebih tinggi (188.90 kali ganda) berbanding gel colchicin 
bukan ethosom. Gel TET 2 dipilih sebagai formulasi akhir gel etosom optimum.  
Kajian kestabilan gel TET 2 menunjukkan bahawa formulasi stabil pada keadaan 
penyimpanan 4 ± 2 °C. Anggaran jangka hayat formulasi gel TET 2 adalah 14.44 
bulan. Kesimpulannya, formulasi gel colchicin etosom untuk penghantaran 
transdermal telah berjaya disediakan, dan ia mungkin berguna sebagai laluan alternatif 
kepada pemberian colchicin secara oral. 
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FORMULATION AND EVALUATION OF COLCHICINE LOADED 
ETHOSOMAL GEL FOR TRANSDERMAL DELIVERY 
 
ABSTRACT 
                   Colchicine is used for the treatment of gout, pseudo-gout and familial 
Mediterranean fever.  It is known to have low therapeutic index and low oral 
bioavailability due to extensive first pass effect, and  also associated with sever 
gastrointestinal side effects following oral administration. To overcome its oral intake 
drawbacks, colchicine loaded ethosomal gels were prepared in an attempt to deliver 
the drug transdermally. The three types of ethosomal nanocarriers were prepared using 
the cold method. Five sets of factorial designs experiments were conducted, one of 23 
for classical ethosomes, one of 24 for binary ethosomes, and three of 24 for 
transethosomes.  Ethosomal systems with vesicular size ≤ 150 nm, polydispersity 
index (PdI) ≤ 0.3, and zeta potential (ZP) ≥ -20 mV were further investigated for drug 
incorporation studies. The optimized ethosomal systems with entrapment efficiency > 
75 % were then incorporated into gel base (Carbopol 940®). The prepared ethosomal 
gels were characterized for vesicular size, PdI, ZP, pH, viscosity and yield values. All 
the formulated ethosomal gels exhibited non-Newtonian plastic flow with no 
thixotropy. Two optimized ethosomal gels were selected TET 2 and TENa 4 gels. TET 
2 gel possessed mean vesicular size, PdI, ZP, pH, viscosity and yield values of 111.4 
± 1.6 nm, 0.157 ± 0.01, -40.56 ± 5.32 mV, 6.74 ± 0.05, 66.25 ± 2.75 Pa.s, and 131.91 
± 1.94 Pa, respectively. While TENa 4 gel possessed mean vesicular size, PdI, ZP, PH, 
viscosity and yield value of 110.5 ± 1.1 nm, 0.162 ± 0.014, -43.54 ± 2.56 mV, 6.81 ± 
0.04, 55.68 ± 0.76 Pa.s, 122.71 ± 0.99 Pa, respectively. HPLC method was developed 
xxii 
 
and validated for the quantification of colchicine in ethosomal gel and dissolution 
media. Ex-vivo skin permeation studies were conducted to evaluate and compare the 
skin permeation parameters between the optimized ethosomal formulations and the 
non-ethosomal gel. The TET 2 gel formulation had higher skin permeation (188.90 
folds) compared to non-ethosomal colchicine gel. The TET 2 gel was selected as the 
final optimized ethosomal gel formulation. The stability studies of TET 2 gel 
formulation revealed that the formula was stable at the storage condition of (4 ± 2 °C). 
The estimated shelf life for the TET 2 gel was estimated and was found to be 14.44 
months. In conclusion, colchicine ethosomal gel formulation for transdermal delivery 
was successfully prepared, and could be useful alternative route to oral administration 
of colchicine. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Gout 
Gout is a form of inflammatory arthritis where swelling and severe pain develop in 
joints, and negatively interfering with patient’s basic daily activities. It was first 
recognized in 2640 BC by the Egyptians (Omole et al., 2009). The worldwide reported 
prevalence of gout ranges from 0.1 % to approximately 10 %, while its incidence vary 
from 0.3 to 6 cases per 1,000 person-years. Over the past 50 years, the global burden 
of gout management was substantial, and seems to be increasing in many parts of the 
world (Kuo et al., 2015). Gout can manifest as acute or chronic arthritis. 
Acute gout is an intense acute inflammatory reaction that occurs due to articular 
deposits of monosodium urate (MSU) crystals. It is one of the most painful conditions 
experienced by humans (Martillo et al., 2014). Acute gout typical symptoms include 
sever red, hot, and swollen joint with an excruciating pain. The acute form of the 
disease may advance to chronic gout if not properly treated. Acute gout treatment relies 
on various therapeutic approaches such as anti-inflammatory agents including 
nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, uricosuric agents and 
corticosteroids (Choi et al., 2005), as well as systemic and intraarticular 
glucocorticoids, and biological agents that inhibit the action of interleukin (IL)-1 beta 
(Terkeltaub, 2010). In 2009, the United States food and drug administration (FDA) 
approved colchicine for treatment of acute gout. A scheduled oral dose for the first 24 
hours of the attack was set with an initial dose of 1.2 mg, one hour later another 0.6 
2 
 
mg is administrated, making a sum of 1.8 mg as a total dose on the first day of therapy 
(Burns & Wortmann, 2012)  
Chronic gout is a progressive disorder of urate metabolism characterized by 
symptomatic hyperuricemia, and monosodium urate crystals deposition in joints as 
well as soft tissues (Novak et al., 2007), which leads to a series of repeated pain 
episodes, as well as inflammation and degenerative ramification, in addition to joint 
damage and motion loss. The treatment of chronic gout goal is to completely dissolve 
MSU crystals and prevent new crystals formation. To achieve such status, the serum 
urate, and uric acid levels within the tissues and joints should decrease below MSU 
saturation point (Perez, 2009), by using uricosuric agents such as allopurinol (> 300 
mg), and  prophylactic colchicine doses (0.5 – 1 mg daily), and/or a non-steroidal anti-
inflammatory drug (NSAID) (Roddy et al., 2007). 
 
1.2 Pseudo-gout  
It is known as acute attacks of synovitis due to calcium pyrophosphate dihydrate 
(CPPD) crystals. Clinically, the disease looks like gouty arthritis. CPPD crystals 
deposition can lead to symptoms like septic arthritis, as well as poly-articular 
inflammatory arthritis which usually are misdiagnosed as rheumatoid arthritis or 
degenerative osteoarthritis (McCarthy, 2008). The diagnosis of pseudo-gout is 
conducted by the demonstration of CPPD crystals in synovial fluid. Both gout and 
pseudo-gout can also coexist in a single inflammatory effusion, as 20 % of patients 
with CPPD will have hyperuricemia, and later, a quarter of these patients will develop 
gout (Rosenthal., 2005). The current available treatments of pseudo-gout are limited 
to fixing the ongoing metabolic abnormalities, and treating their associated symptoms, 
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these treatments include NSAIDs, colchicine, corticosteroids and adrenocorticotropic 
hormone (Choy, 2005). 
1.3 Familial Mediterranean fever (FMF) 
Familial Mediterranean fever (FMF) is a hereditary inflammatory disease 
characterized by recurrent febrile episodes accompanied by peritonitis, pericarditis, 
pleuritis and/or arthritis, it is sometimes associated with an erysipelas-like skin rash. 
Serious complications can happen if the disease is not treated such as end-stage renal 
disease and malabsorption secondary to amyloid deposition in the kidneys and 
digestive tract, male and female infertility, and growth retardation in children (Zadeh 
et al., 2011). FMF treatment relies mainly on preventing the development of painful 
attacks and amyloidosis. Colchicine is the only available drug for treating FMF and is 
considered as the gold standard in FMF therapy. It is thought to inhibit the increased 
chemotactic activity of neutrophils during FMF attacks (Ben-Chetrit & Levy, 1998). 
Colchicine can also improve height development and weight parameters in children 
with FMF (Ozcakar et al., 2010). A daily lifelong administration of colchicine is 
required to prevent both the fever/pain attacks, and the silent amyloid deposition. 
NSAIDs are used to mask the FMF symptoms of fever and pain. (Zadeh et al., 2011). 
 
1.4 Colchicine 
1.4.1 Physicochemical properties 
Colchicine (C22H25NO6) is a yellowish-white amorphous or crystalline powder with a 
structure described in figure 1.1. It is a potent alkaloid obtained from the dried corns 
and seeds of plants of the genus colchicum, which belongs to Liliaceae family. Among 
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this family, the commonly used plants are colchicum autumnale “meadow saffron” 
and colchicum autumn crocus. The drug has a neutral chemical nature, with a partition 
coefficient (log P) and pKa values of 1.3 and 1.85 respectively. It has a molecular 
weight of 399.437 Da, water solubility of 45 mg/ml and a melting point of 156 °C 
(Singh et al., 2015; Bombuwala et al., 2006). 
 
Fig. 1.1: The chemical structure of colchicine. 
 
1.4.2 Pharmacodynamics 
Colchicine has been used for the treatment of acute gout since more than 2000 years 
ago. It was also used to treat pseudo-gout and familial Mediterranean fever (FMF) for 
several decades. It is highly effective in the treatment of acute gout especially when 
given in the first 12 – 36 hr of the gouty attack (Terkeltaub, 2009). Colchicine relieves 
pain and inflammation of gouty arthritis without altering the metabolism or excretion 
of urates and without other analgesic effects. It produces its anti-inflammatory effects 
by binding to the intracellular protein tubulin, thereby preventing its polymerization 
into microtubules, leading to the inhibition of leukocyte migration and phagocytosis. 
It also inhibits the formation of leukotriene B4 (Katzung et al., 2009).  
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Colchicine oral administration linked to several mild to severe gastrointestinal side 
effects including nausea, vomiting, diarrhea, stomach cramps or pain. (Ahern et al., 
1987). Even at therapeutic doses, around 80 percent of patients will develop these side 
effects (Harris et al., 1999; Putterman et al., 1991) While the intravenous 
administration is associated with potential serious adverse effects including tissue 
necrosis cytopenias, disseminated intravascular coagulation, and death (Evans et al., 
1996), accordingly the intravenous route of administration was banned by the FDA 
(Burns & Wortmann, 2012). 
 
1.4.3 Pharmacokinetics 
Colchicine has a low therapeutic index (Terkeltaub, 2009). After oral administration, 
colchicine is absorbed in the jejunum and ileum with a single zero-order rate process, 
showing a low bioavailability of 25 % to 50 % due to the extensive first pass effect 
(Kesselheim  & Solomon 2010). Within the ﬁrst 24 hours of colchicine intake, 15 % 
to 30 % of it excreted in the urine, and its excretion still can be measured for day 10 
of the intake. Up to two thirds of the drug eliminated via feces. After around one hour 
of oral intake the maximum serum concentration is reached, and it varies between 2.2 
and 6.7 ng/ml (Rochdi et al.,1994; Girre et al.,1989). Serum half-life time of colchicine 
is speculated to be ~10 to 20 hours (Girre et al., 1989; Poffenbarger & Brinkley, 1974). 
In FMF patients with renal amyloidosis and are on hemodialysis, it was found that the 
drug elimination half-life was increased signiﬁcantly (400 %), and total clearance was 
reduced compared to healthy patients (Ben-Chetrit et al.,1994).  
 
 
6 
 
1.5 Skin and the transdermal drug delivery 
1.5.1 Skin structure 
The skin covers a total body surface area of approximately 1.8 m2, it is providing the 
contact between the human body and the outer environment. It is the largest and most 
readily accessible organ of the body, serving as a potential route of drug administration 
for systemic effects. Skin has three main layers namely: the epidermis which is the 
outermost layer of skin, beneath the epidermis layer there is the dermis layer which 
contains tough connective tissue, hair follicles, and sweat glands, the third deeper layer 
is the subcutaneous tissue (hypodermis) layer which is made of fat and connective 
tissue.  The epidermis is itself divided into at least four separate parts, a fifth part is 
present in some areas of our body.  The order from the most superficial layer of the 
epidermis to the deepest, these layers (strata) are: the stratum corneum, stratum 
lucidum, stratum granulosum, stratum spinosum and stratum basale. One of the main 
challenges for percutaneous drug delivery is the nearly insuperable nature of stratum 
corneum layer of the epidermis (Barry, 2001), its permeability is approximately 1000 
times less than other biological membranes and this is due to the (brick and mortar) 
arrangement of corneocytes, flattened mononucleated keratinocytes, with interspersed 
lipids and proteins (Hadgraft, 2001a; Hadgraft, 2001b).  
1.5.2 Transdermal drug delivery 
Transdermal drug delivery is currently one of the most appealing alternatives to oral 
drug delivery as well as hypodermic injection route. Transdermal drug delivery 
systems offer many advantages, such as avoidance of first-pass metabolism by the 
liver, controlled delivery of drugs, reduced dosing frequency, and improved patient 
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compliance, as they are noninvasive and can be self-administered (Prausnitz & Langer, 
2008; Schoellhammer et al., 2014). 
The first transdermal patch containing scopolamine for the treatment of motion 
sickness was approved in the US in 1979. A decade later, nicotine patches became the 
first transdermal blockbuster. Till 2008 a variety of 19 transdermal delivery systems 
for single or multiple drug delivery were available in the market such as (fentanyl HCl, 
methylphenidate, selegiline and rotigotine) with an estimation of more than one billion 
transdermal patches that are manufactured each year (Prausnitz & Langer, 2008). 
 
1.6 Ethosomal nanocarriers 
A new era of research in the field of transdermal drug delivery was opened with the 
use of liposomes for topical delivery of triamcinolone (Mezei & Gulasekharam, 1980),  
and since then a wide range of novel lipid-based vesicular systems were developed. 
The deformable or elastic liposomes which are currently known as transfersomes® 
were introduced by Cevc and Blume in 1992 (Cevc & Blume, 1992), and followed by 
the innovative work of Elka Touitou and her team (Touitou et al., 1996), that led to the 
discovery of a novel lipid vesicular system called ethosomes. Ethosomal systems differ 
from liposomes because they contain relatively high concentrations of ethanol in 
addition to phospholipids and water (Touitou et al., 2000). New generations of 
ethosomal systems have been introduced since then by adding other compounds to the 
basic ethosomal formula in an attempt to enhance the vesicular characteristics and the 
skin permeation. 
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1.6.1 Ethosomal systems classification 
Ethosomal systems are classified into three classes on the basis of their compositions 
namely: classical ethosomes, binary ethosomes, and transethosomes (Figure 1.2) 
(Abdulbaqi et al., 2016). 
 
Fig. 1.2:  Schematic representations of the different types of ethosomal systems. 
 
1.6.1(a)Classical ethosomes 
Classical ethosomes are a modification of classical liposomes and are composed of 
phospholipids, high concentration of ethanol up to 45 %w/w and water. The classical 
ethosomes were reported to be superior over the classical liposomes for transdermal 
drug delivery because they have smaller size, negative zeta potential, higher 
entrapment efficiency. Moreover, classical ethosomes showed better skin permeation 
and stability profile compared to classical liposomes (Touitou et al., 2000; Sarwa et 
al., 2014; Jain et al.,2014). The molecular weights of drugs entrapped in classical 
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ethosomes were ranging from 130.077 Daltons to 24 K Daltons (Zhang et al., 2012; 
Mishra et al., 2010). 
 
1.6.1(b) Binary Ethosomes 
Binary ethosomes were first introduced by Zhou et al in 2010 (Zhou et al., 2010). 
Basically, they were developed by adding another type of alcohol to the classical 
ethosomes. The most commonly used alcohols in binary ethosomes are propylene 
glycol (PG) and isopropyl alcohol (IPA) (Li et al., 2012; Zhang et al., 2012; Akhtar & 
Pathak, 2012; Dave et al., 2010; Shen et al., 2014). 
 
1.6.1(c) Transethosomes 
Transethosomes are the new generation of ethosomal systems which were first 
reported by Song et al in 2012 (Song et al., 2012). This ethosomal system contains the 
basic components of classical ethosomes and additional compound such as a 
penetration enhancer or an edge activator (surfactant) in their formula. These novel 
vesicles were developed in an attempt to combine the advantages of classical 
ethosomes and deformable liposomes (Transfersomes®) in one formula to produce 
transethosomes. Many researchers have reported superior properties of transethosomes 
over classical ethosomes (Ainbinder & Touitou, 2011; Bragagni et al., 2012; Meng et 
al., 2013; Chen et al., 2014; Chenet al., 2014; Fang et al., 2008; Ascenso et al., 2015). 
Different types of edge activators and penetration enhancers have been investigated to 
produce ethosomal systems with better characteristics. Transethosomes were reported 
to entrap drugs with molecular weights ranging from 130.077 Daltons to 200–325 K 
Daltons (Ainbinder & Touitou, 2011; Chen et al., 2014). Table 1.1 shows the 
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comparison of classical ethosomes, binary ethosomes and transethosomes properties 
in their initial suspension form.  
Table 1.1: Comparison of Classical Ethosomes, Binary Ethosomes and 
Transethosomes 
 
Parameter Classical 
ethosomes 
Binary ethosomes Transethosomes 
Composition 1. Phospholipids 
2. Ethanol 
3. Stabilizer 
5. Charge inducer 
6. Water 
7. Drug/agent 
1. Phospholipids 
2. Ethanol 
3. Propylene glycol 
(PG) or other alcohol 
4. Charge inducer 
5. Water 
6. Drug/Agent 
1. Phospholipids 
2. Ethanol 
3. Edge activator 
(surfactant) or 
penetration 
enhancer 
4. Charge inducer 
5. Water 
6. Drug/agent 
Morphology Spherical Spherical Regular or 
irregular spherical 
shapes 
Size Smaller than the 
classical 
liposomes 
Equal to or smaller 
than classical 
ethosomes 
Size based on 
type and 
concentration of 
penetration 
enhancer or edge 
activator used 
Zeta Potential Negatively 
charged 
Negatively charged Positively or 
negatively 
charged 
Entrapment 
efficiency 
Higher than 
classical 
liposomes 
Typically higher than 
classical ethosomes 
Typically higher 
than classical 
ethosomes 
Skin permeation Typically higher 
than classical 
liposomes 
Typically equal to or 
higher than classical 
ethosomes 
Typically higher 
than classical 
ethosomes 
Stability More stable than 
classical 
liposomes 
More stable than 
classical ethosomes 
No particular 
trend determined 
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1.6.2 Mechanisms of ethosomal system skin permeation 
Ethanol and phospholipids are reported to act synergistically to enhance the skin 
permeation of drugs in ethosomal formulations. Ethanol fluidizes the lipid bilayers of 
the ethosomal vesicles and the stratum corneum simultaneously, changing the 
arrangement and decreasing the density of skin lipids. Therefore, the highly malleable 
and soft vesicles of an ethosomal system will penetrate the altered structure of the 
stratum corneum and create a pathway through the skin. The release of the therapeutic 
agent occurs by the fusion of these vesicles into cell membranes in the deeper layers 
of the skin (Touitou et al., 2000; Ainbinder et al., 2010; Singh et al., 2014). It is 
suggested that transethosomes have superior skin-permeation properties over classical 
ethosomes. This is because transethosomes contain both ethanol and the edge activator 
or the penetration enhancer, which both act together to increase vesicular malleability 
and skin-lipid perturbation (Bragagni et al., 2012; Ascenso et al., 2015). A proposed 
mechanism is illustrated in figure 1.3. 
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Fig 1.3: Proposed mechanism for permeation of molecules from ethosomal system 
through the skin. Notes: (A) Normal skin; (B) Skin-lipid perturbation by ethanol 
effects; (C) Penetration of the soft malleable ethosomal system vesicles. 
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1.6.3 Preparation methods 
1.6.3(a) The classical cold method 
This is the simplest and most widely used method for the preparation of ethosomal 
systems. The organic phase is obtained by dissolving the phospholipids, (in addition 
to the surfactant or penetration enhancer for the preparation of transethosomes) in 
ethanol, or in mixture of solvents (ethanol/PG for binary ethosomes) (Zhang et al., 
2012), at room temperature (Cortesi et al., 2010), or at 30 °C (Touitou et al., 2000). 
The used aqueous phase is either water (Dubey et al., 2007; De la Presa et al., 2009; 
Chourasia et al.,2011), buffer solution (Dubey et al., 2010; Cortesi et al., 2010) or 
normal saline solution (Raza et al., 2013). The aqueous phase is added to the organic 
phase in a fine stream (Touitou et al., 2000) dropwise (Zhou et al., 2010) or using a 
syringe pump at a constant rate of 175 or 200 µl/min (Paolino et al., 2005). The mixture 
is stirred at a speed of 700 – 2,000 rpm (Touitou et al., 2000; Chourasia et al., 2011; 
Kaur & Saraf, 2011; Chen et al., 2010) using an overhead (Touitou et al., 2001) or 
magnetic (Elsayed et al., 2006) stirrer. The intended drug for incorporation within the 
ethosomal system will be dissolved in either the aqueous or the organic phase, 
depending on its physicochemical properties.  
 
1.6.3(b) The ethanol injection–sonication method 
In this method, the organic phase containing the dissolved phospholipid in ethanol is 
injected to the aqueous phase, using a syringe system (Zhaowu et al., 2009) at a flow 
rate of 200 µl/min, then homogenized with an ultrasonic probe for 5 min (Liu et al., 
2011). 
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1.6.3(c) The hot method 
In one vessel, phospholipid is dispersed in water and placed in a water bath at 40 °C 
until a colloidal suspension is obtained. In another vessel, ethanol is heated to 40 °C 
and then added dropwise to the phospholipid dispersion, under continuous mixing 
using a mechanical or magnetic stirrer (Ashoniya & Meenakshi, 2011). The drug is 
dissolved in either the organic or the aqueous phase, based on its 
hydrophilic/hydrophobic properties. 
 
1.6.3(d) The thin-film hydration method 
In this method the phospholipid is first dissolved in chloroform only (Park et al., 2014) 
or a chloroform–methanol mixture at ratios of 3:1 or 2:1 in a clean, dry, round-bottom 
flask, later, organic solvents are removed by a rotary vacuum evaporator at a 
temperature above the lipid-phase transition temperature. The traces of the solvents 
are removed from the deposited lipid film under vacuum overnight, then the lipid film 
is hydrated with a water–ethanol solution (Lopez-Pinto et al.,2005) or phosphate 
buffered saline–ethanol solution (Mishra et al., 2008). 
 
1.6.3(e) The reverse-phase evaporation method 
This is the least used method and specially designed to produce large unilamellar 
vesicles. The organic phase is prepared by dissolving the phospholipid in diethyl ether 
and then mixing it with the aqueous phase at a ratio of 3:1 v/v in an ultrasonic bath at 
0 °C for 5 min to form a water-in-oil emulsion. The organic solvent is removed under 
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reduced pressure to produce a gel, which turns into a colloidal dispersion upon 
vigorous mechanical agitation (Maestrelli et al., 2009). 
 
1.6.3(f) Transmembrane pH-gradient method 
In this method, the drug is loaded “actively”, based on the pH-gradient difference 
between the acidic interior of the internal phase and the basic exterior of the external 
phase of the ethosomal system. At first, the empty ethosomal suspension is prepared 
using any of the aforementioned methods, but the aqueous phase or the hydration 
process uses an acidic buffer (usually citrate buffer, pH 3). Secondly, the active drug 
is loaded into the empty ethosomal suspension, followed by continuous stirring. In 
order to make the external phase more alkaline and to establish the pH gradient 
between the acidic internal (pH 3) and basic external phases of the ethosomal system, 
an alkali, usually a sodium hydroxide solution of 0.5 M is added to make the external 
pH 7.4. In the third stage, the ethosomal system is incubated at a specified time and 
temperature (30 – 60 °C) to give the opportunity for the unionized drug to actively 
pass the bilayer of the ethosomal vesicles and get entrapped (Zhou et al., 2010). 
 
1.7 Literature review 
The ability of ethosomal systems to penetrate intact skin, delivering molecules with 
diverse physicochemical properties in therapeutic amounts to the blood circulation, 
has been reported by many researchers (Abdulbaqi et al., 2016). For instance, the 
pharmacokinetics and pharmacodynamics effects of a valsartan-loaded ethosomal 
system were studied in albino Wistar rats. The bioavailability of transdermal 
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ethosomal valsartan was significantly higher (3.03 times) than the oral valsartan 
suspension; the area under the concentration–time profile curve from time 0 to infinity 
for the transdermal ethosomal formulation was 177,298.82±665.01 ng/ml/hr., while 
for the oral suspension it was 55,554.54±774.01 ng/ml/hr. The dose of valsartan used 
in both routes was 3.6 mg/kg. The reported maximum drug concentration (Cmax) and 
the time taken to reach maximum concentration (Tmax) values for the oral 
administration were 13,100±101.12 ng/ml and 1±0.01 hr, respectively. The Cmax and 
Tmax values for the transdermal route were 7,944±134.32 ng/ml and 5.0±0.83 hr., 
respectively (Ahad et al., 2013). Ethosomal valsartan was shown to effectively reduce 
blood pressure by 34.11 % for 48 hr in hypertensive rats (Ahad et al., 2015). 
The incorporation of ethosomal dispersions in suitable vehicles like gels, patches, and 
creams represents an important step to get better skin-permeation and therapeutic 
results. Several researchers have studied the skin permeation and disposition properties 
of various drugs from ethosomal gels, and reported the high efficiency and superiority 
of these formulations in dermal or transdermal drug delivery over the traditional or 
marketed gels or creams. (Puri & Jain, 2012) compared the in vitro skin permeation 
properties of 5-fluorouracil from ethosomal gel and marketed cream using Franz 
diffusion cell and albino rat skin, and found that the transdermal flux of 5-fluorouracil 
from ethosomal gels was 4.9 folds higher than the marketed cream. Moreover, the skin 
disposition of the drug from the ethosomal gel was 9.4-fold higher than the marketed 
cream (Puri & Jain, 2012). Other researchers found that in vitro transdermal flux of 
aceclofenac from ethosomal gel was higher (226.1 μg/cm2/hr) than Zynac gel (131.1 
μg/cm2/hr) (Dave et al., 2010). The development of colchicine loaded ethosomal gel 
for transdermal delivery may offer a new route for administration of this venerable 
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drug to solve the several dose dependent side effects associated with its oral 
administration and enhance its bioavailability. 
 
1.8 Problem statement 
Colchicine is a highly effective drug in the treatment of gout, pseudo-gout, FMF and 
many other illnesses, but it is known to have a low therapeutic index and oral 
bioavailability of 25 % to 50 % due to the extensive first-pass metabolism, its oral 
administration is associated with mild to severe gastrointestinal side effects including: 
abdominal cramps, pain, nausea, vomiting and diarrhea that will develop in around 80 
percent of patients. Colchicine was used to be administered intravenously until it was 
banned by the United States food and drug administration (FDA) in 2008 due to its 
potential and serious adverse effects such as tissue necrosis cytopenias, disseminated 
intravascular coagulation, and even death. 
Therefore, colchicine transdermal administration by ethosomal gels may offer an 
alternative route of administration of this drug to overcome its adverse reactions, and 
low oral bioavailability problems associated with the oral route. 
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1.9 Study Objectives 
The objectives of the proposed study are: 
I. To optimize colchicine ethosomal systems using 23 and 24 factorial designs. 
II. To develop and validate an HPLC method for the quantification of colchicine 
in ethosomal gel and in the release media. 
III. To formulate and optimize colchicine loaded ethosomal gel. 
IV. To evaluate the stability of the optimized gel formulation. 
V. To study the skin permeation behavior of the drug from the optimized gel 
formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
CHAPTER 2 
DEVELOPMENT AND CHARACTERIZATION OF COLCHICINE 
ETHOSOMAL SYSTEMS 
 
2.1 Introduction 
Colchicine is used for the treatment of acute gout, familial Mediterranean fever (FMF) 
and pseudo-gout (Martinon et al., 2006). However, colchicine is known to have low 
oral bioavailability (25 – 50 %) due to the extensive first-pass metabolism (Ben-Chetrit 
& Levy, 1998) and low therapeutic index (Terkeltaub, 2009). 
Oral administration of colchicine is causing severe gastrointestinal side effects, 
including abdominal cramps and pain, nausea, vomiting and diarrhea (Niel & 
Scherrmann, 2006). 
To overcome these drawbacks, and to improve colchicine bioavailability, some 
researchers studied and prepared microemulsions (Ganju et al., 2012) nanoemulsions 
(Shen et al., 2011), transdermal patches (Kumar et al., 2012), iontophoresis (Kulkarni 
et al., 1996) and elastic liposomes (Singh et al., 2009). 
Ethosomal systems are novel nanocarriers especially designed for the delivery of drugs 
dermally or transdermally, and may represent useful tools for the delivery of 
colchicine. Therefore, the aim of present study was to prepare colchicine ethosomes 
for transdermal delivery. The three types of ethosomal systems were prepared namely: 
classical ethosomes (CE), binary ethosomes (BE) and transethosomes (TE). The 23 and 
24 factorial designs were used in the optimization of ethosomal formulations.  
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2.2 Materials 
Colchicine (purity > 97 %) was purchased from (Acros organics, New Jersey, USA). 
Phospholipon 90G® (PL90G) (contains > 90 % Phosphatidylcholine from soybean) 
generously donated by (Lipoid LLC, New Jersey, USA). Absolute ethanol (purity ~ 
99.7 %) was bought from (Fine Chemicals Inc., USA). Tween 20® (purity ≥ 99 %) and 
sodium stearate were purchased from (R & M Chemicals, Essex, UK). Sodium 
taurocholate, cholesterol and Sephadex® G-25 were bought from (Sigma-Aldrich, St. 
Louis, MO, USA). Propylene glycol (PG) acid was obtained from (QRëC, Selangor, 
Malaysia). Labrafil® M 1944 CS (Oleoyl macrogol-6 glycerides EP) was purchased 
from (Gattefossé, Lyon, France). Ultrapure water was prepared by Elga PURELAB 
Classic UVF water purification system, France. 
 
2.3 Methods 
2.3.1 Preparation of the ethosomal systems  
The three types of ethosomal systems namely classical ethosomes (CE), binary 
ethosomes (BE) and transethosomes (TE) were prepared using the cold method 
(Abdulbaqi et al., 2016; Touitou et al., 2000). In this method the organic phase was 
obtained by dissolving the PL90G at 30 °C in ethanol for preparation of CE or mixture 
of solvents (ethanol/polyethylene glycol) for the preparation of BE. Surfactants (either 
Tween 20®, Sodium taurocholate or Labrafil®) were added into organic phase for the 
preparation of TE. The aqueous phase (Ultrapure water) was heated to 30ºC as well 
and then added to organic phase dropwise with continuous stirring at 1200 rpm, using 
magnetic stirrer. The mixing continued for 45 min to get the ethosomal dispersions 
which are further subjected to size-reduction process by multiple extrusions through 
